Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Behan, Miles W. (8862299400)"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Stepwise provisional versus systematic culotte for stenting of true coronary bifurcation lesions: five-year follow-up of the multicentre randomised EBC TWO Trial
    (2023)
    Arunothayaraj, Sandeep (36140221200)
    ;
    Behan, Miles W. (8862299400)
    ;
    Lefèvre, Thierry (13608617100)
    ;
    Lassen, Jens F. (57189389659)
    ;
    Chieffo, Alaide (57202041611)
    ;
    Stankovic, Goran (59150945500)
    ;
    Burzotta, Francesco (7003405739)
    ;
    Pan, Manuel (7202544866)
    ;
    Ferenc, Miroslaw (8933716300)
    ;
    Hovasse, Thomas (25627893900)
    ;
    Spence, Mark S. (7103007124)
    ;
    Brunel, Philippe (7006007671)
    ;
    Cotton, James M. (7102218822)
    ;
    Cockburn, James (43661048500)
    ;
    Carrié, Didier (7006798967)
    ;
    Baumbach, Andreas (56962775900)
    ;
    Maeng, Michael (20034699800)
    ;
    Louvard, Yves (7004523655)
    ;
    Hildick-Smith, David (8089365300)
    Background: The multicentre European Bifurcation Club Trial (EBC TWO) showed no significant differences in 12-month clinical outcomes between patients randomised to a provisional stenting strategy or systematic culotte stenting in non-left main true bifurcations. Aims: This study aimed to investigate the 5-year clinical results of the EBC TWO Trial. Methods: A total of 200 patients undergoing stent implantation for non-left main bifurcation lesions were recruited into EBC TWO. Inclusion criteria required a side branch diameter ≥2.5 mm and side branch lesion length >5 mm. Five-year follow-up was completed for 197 patients. The primary endpoint was the composite of all-cause mortality, myocardial infarction, or target vessel revascularisation. Results: The mean side branch stent diameter was 2.7±0.3 mm and mean side branch lesion length was 10.3±7.2 mm. At 5-year follow-up, the primary endpoint occurred in 18.4% of provisional and 23.7% of systematic culotte patients (hazard ratio [HR] 0.75, 95% confidence interval [CI]: 0.41-1.38). No significant differences were identified individually for all-cause mortality (7.8% vs 7.2%, HR 1.11, 95% CI: 0.40-3.05), myocardial infarction (8.7% vs 13.4%, HR 0.64, 95% CI: 0.27-1.50) or target vessel revascularisation (6.8% vs 9.3%, HR 1.12, 95% CI: 0.37-3.34). Stent thrombosis rates were also similar (1.9% vs 3.1%, HR 0.63, 95% CI: 0.11-3.75). There was no significant interaction between the extent of side branch disease and the primary outcome (p=0.34). Conclusions: In large non-left main true bifurcation lesions, the use of a systematic culotte strategy showed no benefit over provisional stenting for the composite outcome of all-cause mortality, myocardial infarction, or target vessel revascularisation at 5 years. The stepwise provisional approach may be considered preferable for the majority of true coronary bifurcation lesions. © Europa Digital & Publishing 2023. All rights reserved.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The EBC TWO Study (European Bifurcation Coronary TWO): A Randomized Comparison of Provisional T-Stenting Versus a Systematic 2 Stent Culotte Strategy in Large Caliber True Bifurcations
    (2016)
    Hildick-Smith, David (8089365300)
    ;
    Behan, Miles W. (8862299400)
    ;
    Lassen, Jens F. (57189389659)
    ;
    Chieffo, Alaide (57202041611)
    ;
    Lefèvre, Thierry (13608617100)
    ;
    Stankovic, Goran (59150945500)
    ;
    Burzotta, Francesco (7003405739)
    ;
    Pan, Manuel (7202544866)
    ;
    Ferenc, Miroslaw (8933716300)
    ;
    Bennett, Lorraine (35847475900)
    ;
    Hovasse, Thomas (25627893900)
    ;
    Spence, Mark S. (7103007124)
    ;
    Oldroyd, Keith (7003557589)
    ;
    Brunel, Philippe (7006007671)
    ;
    Carrie, Didier (7006798967)
    ;
    Baumbach, Andreas (56962775900)
    ;
    Maeng, Michael (20034699800)
    ;
    Skipper, Nicola (56108237700)
    ;
    Louvard, Yves (7004523655)
    Background-For the treatment of coronary bifurcation lesions, a provisional strategy is superior to systematic 2-stent techniques for the most bifurcation lesions. However, complex anatomies with large side branches (SBs) with significant ostial disease length are considered by expert consensus to warrant a 2-stent technique upfront. This consensus view has not been scientifically assessed. Methods and Results-Symptomatic patients with large caliber true bifurcation lesions (SB diameter ≥2.5 mm) and significant ostial disease length (≥5 mm) were randomized to either a provisional T-stent strategy or a dual stent culotte technique. Two hundred patients aged 64±10 years, 82% male, were randomized in 20 European centers. The clinical presentations were stable coronary disease (69%) and acute coronary syndromes (31%). SB stent diameter (2.67±0.27 mm) and length (20.30±5.89 mm) confirmed the extent of SB disease. Procedural success (provisional 97%, culotte 94%) and kissing balloon inflation (provisional 95%, culotte 98%) were high. Sixteen percent of patients in the provisional group underwent T-stenting. The primary end point (a composite of death, myocardial infarction, and target vessel revascularization at 12 months) occurred in 7.7% of the provisional T-stent group versus 10.3% of the culotte group (hazard ratio, 1.02; 95% confidence interval, 0.78-1.34; P=0.53). Procedure time, X-ray dose, and cost all favored the simpler procedure. Conclusions-When treating complex coronary bifurcation lesions with large stenosed SBs, there is no difference between a provisional T-stent strategy and a systematic 2-stent culotte strategy in a composite end point of death, myocardial infarction, and target vessel revascularization at 12 months. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT 01560455. © 2016 American Heart Association, Inc.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback